Suzuken Co Ltd
TSE:9987

Watchlist Manager
Suzuken Co Ltd Logo
Suzuken Co Ltd
TSE:9987
Watchlist
Price: 5 562 JPY -0.5% Market Closed
Market Cap: ¥401.4B

Suzuken Co Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Suzuken Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Suzuken Co Ltd
TSE:9987
Operating Income
¥34.6B
CAGR 3-Years
5%
CAGR 5-Years
17%
CAGR 10-Years
6%
A
Alfresa Holdings Corp
TSE:2784
Operating Income
¥36.7B
CAGR 3-Years
7%
CAGR 5-Years
2%
CAGR 10-Years
0%
Toho Holdings Co Ltd
TSE:8129
Operating Income
¥17B
CAGR 3-Years
3%
CAGR 5-Years
17%
CAGR 10-Years
0%
Medipal Holdings Corp
TSE:7459
Operating Income
¥53.4B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
3%
Ship Healthcare Holdings Inc
TSE:3360
Operating Income
¥24.1B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
6%
As One Corp
TSE:7476
Operating Income
¥12.4B
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
7%
No Stocks Found

Suzuken Co Ltd
Glance View

Market Cap
401.4B JPY
Industry
Health Care

In the intricate tapestry of Japan’s healthcare landscape, Suzuken Co., Ltd. emerges as a key player, deftly weaving its capabilities in the pharmaceutical distribution sector. Founded in 1932, Suzuken has evolved from humble beginnings into a giant distributor, serving as a crucial conduit between pharmaceutical manufacturers and healthcare institutions. The company's core operation revolves around the efficient distribution of pharmaceuticals, medical devices, and related healthcare products. From temperature-sensitive vaccines to essential life-saving medicines, Suzuken ensures that these critical items reach hospitals, clinics, and pharmacies across Japan promptly and safely. This role not only underscores the importance of logistics in healthcare but also highlights Suzuken's commitment to ensuring that patients’ needs are met with reliability and precision. Moreover, Suzuken’s revenue engine is powered by its extensive network of subsidiaries and a streamlined supply chain, enabling it to fulfill diverse customer demands while optimizing costs. The company strategically balances its portfolio by engaging in the manufacture of certain generic drugs and offering medical information services, thus enhancing its value proposition. This diversification aids in stabilizing revenue streams amidst the volatility of drug pricing and policy changes in the healthcare sector. By maintaining strong partnerships with numerous pharmaceutical firms and leveraging technological advancements in logistics, Suzuken bolsters its position as a stalwart in the industry. In doing so, it creates a ripple effect that supports the broader ecosystem—ensuring timely healthcare delivery to Japan's aging population and contributing significantly to the national goal of a resilient healthcare infrastructure.

Intrinsic Value
14 219.38 JPY
Undervaluation 61%
Intrinsic Value
Price ¥5 562

See Also

What is Suzuken Co Ltd's Operating Income?
Operating Income
34.6B JPY

Based on the financial report for Dec 31, 2025, Suzuken Co Ltd's Operating Income amounts to 34.6B JPY.

What is Suzuken Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
6%

Over the last year, the Operating Income growth was -9%. The average annual Operating Income growth rates for Suzuken Co Ltd have been 5% over the past three years , 17% over the past five years , and 6% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett